Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash to Debt 0.79
SKBI's Cash to Debt is ranked lower than
66% of the 682 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.38 vs. SKBI: 0.79 )
SKBI' s 10-Year Cash to Debt Range
Min: 0   Max: No Debt
Current: 0.79

Equity to Asset 0.71
SKBI's Equity to Asset is ranked higher than
64% of the 546 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.63 vs. SKBI: 0.71 )
SKBI' s 10-Year Equity to Asset Range
Min: -1563   Max: 0.91
Current: 0.71

-1563
0.91
Interest Coverage 21.26
SKBI's Interest Coverage is ranked lower than
71% of the 361 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6896.27 vs. SKBI: 21.26 )
SKBI' s 10-Year Interest Coverage Range
Min: 1   Max: 9999.99
Current: 21.26

1
9999.99
F-Score: 6
Z-Score: 1.91
M-Score: -2.58
WACC vs ROIC
7.93%
8.95%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating margin (%) 25.69
SKBI's Operating margin (%) is ranked higher than
89% of the 645 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.91 vs. SKBI: 25.69 )
SKBI' s 10-Year Operating margin (%) Range
Min: -50916.67   Max: 38.08
Current: 25.69

-50916.67
38.08
Net-margin (%) 22.48
SKBI's Net-margin (%) is ranked higher than
90% of the 645 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 5.82 vs. SKBI: 22.48 )
SKBI' s 10-Year Net-margin (%) Range
Min: -75166.67   Max: 29.63
Current: 22.48

-75166.67
29.63
ROE (%) 9.78
SKBI's ROE (%) is ranked higher than
60% of the 673 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.24 vs. SKBI: 9.78 )
SKBI' s 10-Year ROE (%) Range
Min: -56375   Max: 80.86
Current: 9.78

-56375
80.86
ROA (%) 7.49
SKBI's ROA (%) is ranked higher than
69% of the 690 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.16 vs. SKBI: 7.49 )
SKBI' s 10-Year ROA (%) Range
Min: -60200   Max: 37.93
Current: 7.49

-60200
37.93
ROC (Joel Greenblatt) (%) 11.90
SKBI's ROC (Joel Greenblatt) (%) is ranked higher than
53% of the 686 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 10.15 vs. SKBI: 11.90 )
SKBI' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -6431.58   Max: 105.87
Current: 11.9

-6431.58
105.87
Revenue Growth (3Y)(%) -5.90
SKBI's Revenue Growth (3Y)(%) is ranked lower than
79% of the 537 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 5.40 vs. SKBI: -5.90 )
SKBI' s 10-Year Revenue Growth (3Y)(%) Range
Min: 0   Max: 44.4
Current: -5.9

0
44.4
EBITDA Growth (3Y)(%) -8.80
SKBI's EBITDA Growth (3Y)(%) is ranked lower than
71% of the 467 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.80 vs. SKBI: -8.80 )
SKBI' s 10-Year EBITDA Growth (3Y)(%) Range
Min: 0   Max: 78.9
Current: -8.8

0
78.9
EPS Growth (3Y)(%) -11.20
SKBI's EPS Growth (3Y)(%) is ranked lower than
67% of the 439 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.40 vs. SKBI: -11.20 )
SKBI' s 10-Year EPS Growth (3Y)(%) Range
Min: 0   Max: 53.3
Current: -11.2

0
53.3
» SKBI's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

SKBI Guru Trades in

Q3 2014

SKBI Guru Trades in Q3 2014

Jim Simons 14,600 sh (New)
» More
Q4 2014

SKBI Guru Trades in Q4 2014

Jim Simons 12,059 sh (-17.40%)
» More
Q1 2015

SKBI Guru Trades in Q1 2015

Jim Simons 15,800 sh (+31.02%)
» More
» Details

Insider Trades

Latest Guru Trades with SKBI

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 2.30
SKBI's P/E(ttm) is ranked higher than
98% of the 461 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 30.10 vs. SKBI: 2.30 )
SKBI' s 10-Year P/E(ttm) Range
Min: 0.78   Max: 486.49
Current: 2.3

0.78
486.49
Forward P/E 6.88
SKBI's Forward P/E is ranked higher than
96% of the 266 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 18.66 vs. SKBI: 6.88 )
N/A
PE(NRI) 2.30
SKBI's PE(NRI) is ranked higher than
98% of the 461 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 34.70 vs. SKBI: 2.30 )
SKBI' s 10-Year PE(NRI) Range
Min: 0.78   Max: 450
Current: 2.3

0.78
450
P/B 0.20
SKBI's P/B is ranked higher than
98% of the 656 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.80 vs. SKBI: 0.20 )
SKBI' s 10-Year P/B Range
Min: 0.09   Max: 7.87
Current: 0.2

0.09
7.87
P/S 0.48
SKBI's P/S is ranked higher than
92% of the 637 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.80 vs. SKBI: 0.48 )
SKBI' s 10-Year P/S Range
Min: 0.22   Max: 12.58
Current: 0.48

0.22
12.58
PFCF 1.40
SKBI's PFCF is ranked higher than
98% of the 326 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 27.50 vs. SKBI: 1.40 )
SKBI' s 10-Year PFCF Range
Min: 1.21   Max: 193.75
Current: 1.4

1.21
193.75
POCF 1.32
SKBI's POCF is ranked higher than
98% of the 445 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 26.56 vs. SKBI: 1.32 )
SKBI' s 10-Year POCF Range
Min: 1.32   Max: 99999999.99
Current: 1.32

1.32
99999999.99
EV-to-EBIT 2.49
SKBI's EV-to-EBIT is ranked higher than
98% of the 472 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 26.75 vs. SKBI: 2.49 )
SKBI' s 10-Year EV-to-EBIT Range
Min: 0.6   Max: 44.6
Current: 2.49

0.6
44.6
Shiller P/E 2.10
SKBI's Shiller P/E is ranked higher than
97% of the 308 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 27.18 vs. SKBI: 2.10 )
SKBI' s 10-Year Shiller P/E Range
Min: 0.95   Max: 1090
Current: 2.1

0.95
1090
Current Ratio 2.50
SKBI's Current Ratio is ranked higher than
54% of the 593 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.37 vs. SKBI: 2.50 )
SKBI' s 10-Year Current Ratio Range
Min: 0.01   Max: 9.57
Current: 2.5

0.01
9.57
Quick Ratio 2.02
SKBI's Quick Ratio is ranked higher than
57% of the 593 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.72 vs. SKBI: 2.02 )
SKBI' s 10-Year Quick Ratio Range
Min: 0.01   Max: 7.56
Current: 2.02

0.01
7.56
Days Inventory 347.24
SKBI's Days Inventory is ranked lower than
95% of the 609 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 114.49 vs. SKBI: 347.24 )
SKBI' s 10-Year Days Inventory Range
Min: 14.48   Max: 457.16
Current: 347.24

14.48
457.16
Days Sales Outstanding 263.03
SKBI's Days Sales Outstanding is ranked lower than
97% of the 585 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 72.43 vs. SKBI: 263.03 )
SKBI' s 10-Year Days Sales Outstanding Range
Min: 4.92   Max: 121.67
Current: 263.03

4.92
121.67

Valuation & Return

vs
industry
vs
history
Price/Net Current Asset Value 6.20
SKBI's Price/Net Current Asset Value is ranked higher than
60% of the 285 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.20 vs. SKBI: 6.20 )
SKBI' s 10-Year Price/Net Current Asset Value Range
Min: 0.17   Max: 105.26
Current: 6.2

0.17
105.26
Price/Tangible Book 0.20
SKBI's Price/Tangible Book is ranked higher than
99% of the 592 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.10 vs. SKBI: 0.20 )
SKBI' s 10-Year Price/Tangible Book Range
Min: 0.1   Max: 47.62
Current: 0.2

0.1
47.62
Price/DCF (Projected) 0.20
SKBI's Price/DCF (Projected) is ranked higher than
99% of the 326 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.00 vs. SKBI: 0.20 )
SKBI' s 10-Year Price/DCF (Projected) Range
Min: 0.12   Max: 350
Current: 0.2

0.12
350
Price/Median PS Value 0.40
SKBI's Price/Median PS Value is ranked higher than
96% of the 615 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.00 vs. SKBI: 0.40 )
SKBI' s 10-Year Price/Median PS Value Range
Min: 0.2   Max: 30.14
Current: 0.4

0.2
30.14
Price/Graham Number 0.10
SKBI's Price/Graham Number is ranked higher than
100% of the 405 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.00 vs. SKBI: 0.10 )
SKBI' s 10-Year Price/Graham Number Range
Min: 0.08   Max: 17.7
Current: 0.1

0.08
17.7
Earnings Yield (Greenblatt) 42.30
SKBI's Earnings Yield (Greenblatt) is ranked higher than
98% of the 674 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.60 vs. SKBI: 42.30 )
SKBI' s 10-Year Earnings Yield (Greenblatt) Range
Min: 2.2   Max: 157
Current: 42.3

2.2
157
Forward Rate of Return (Yacktman) 9.24
SKBI's Forward Rate of Return (Yacktman) is ranked higher than
55% of the 304 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.88 vs. SKBI: 9.24 )
SKBI' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -308.6   Max: 15
Current: 9.24

-308.6
15

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Major
Compare:GSK, JNJ, PFE, RHHBY, NVS » details
Traded in other countries:GNJC.Germany,
Skystar Bio-Pharmaceutical Company was incorporated in Nevada on September 24, 1998. The Company is engaged in the research, development, production, marketing, and sales of veterinary healthcare and medical care products. All current operations of the Company are in the People's Republic of China. The Company's operations are carried out by Xi'an Tianxing Bio-Pharmaceutical Co., Limited, a PRC joint stock company that it controls through contractual arrangements originally between Skystar Cayman and Xi'an Tianxing. The Company has four major product lines, namely micro-organism products line; veterinary medicine line; feed additives line; bio-pharmaceutical veterinary vaccine line. Its micro-organism products line includes over 16 products; veterinary medicine line for poultry and livestock includes over 245 products; feed additives line includes over 16 products; and its bio-pharmaceutical veterinary vaccine line includes over 10 products. As of December 31, 2012, the Company had over 4,000 customers in 29 provinces in China, including 2,893 distributors and 1,122 direct customers. Of the 2,893 distributors, 360 are physical stores that have outer signage with its logo and sell products from its four product lines, known as franchise distributors. The Company competes with China Animal Husbandry Industry Co. Ltd. and Qilu Animal Health Production Co., Ltd. in China. In veterinary vaccine products, the Company competes with Xinjiang Tecon Animal Husbandry Bio-technology Co., Ltd. and Inner Mongolia Jinyu Group Stock Company.
» More Articles for SKBI

Headlines

Articles On GuruFocus.com
Skystar Bio-Pharmaceutical to File Financial Results for Third Quarter of Fiscal 2014 on Friday, Nov Nov 14 2014 
Skystar Bio-Pharma Featured on Wide World of Stocks Television Nov 05 2014 
animal vaccination w Oct 11 2011 

More From Other Websites
5:02 pm Skystar Bio Pharmaceutical announces receipt of non-compliance letter due to delay in filing... May 25 2015
Skystar Bio-Pharmaceutical Company Announces Receipt of Nasdaq Non-Compliance Letter Due to Delay in... May 22 2015
SKYSTAR BIO-PHARMACEUTICAL CO Files SEC form 8-K, Notice of Delisting or Failure to Satisfy a... May 22 2015
Skystar Bio-Pharmaceutical Company Announces Receipt of Nasdaq Non-Compliance Letter Due to Delay in... May 22 2015
SKYSTAR BIO-PHARMACEUTICAL CO Files SEC form 8-K, Notice of Delisting or Failure to Satisfy a... Apr 15 2015
Skystar Bio-Pharmaceutical Company Announces Receipt of NASDAQ Non-Compliance Letter Due to Delay in... Apr 15 2015
SKYSTAR BIO-PHARMACEUTICAL CO Files SEC form 8-K, Submission of Matters to a Vote of Security... Dec 05 2014
SKYSTAR BIO-PHARMACEUTICAL CO Financials Nov 21 2014
Skystar Bio-Pharmaceutical Reports Third Quarter Fiscal Year 2014 Financial Results Nov 18 2014
Skystar Bio-Pharmaceutical Reports Third Quarter Fiscal Year 2014 Financial Results Nov 14 2014
SKYSTAR BIO-PHARMACEUTICAL CO Files SEC form 10-Q, Quarterly Report Nov 14 2014
Skystar Bio-Pharmaceutical to File Financial Results for Third Quarter of Fiscal 2014 on Friday,... Nov 14 2014
Skystar Bio-Pharmaceutical to File Financial Results for Third Quarter of Fiscal 2014 on Friday,... Nov 14 2014
Skystar Bio-Pharma Featured on Wide World of Stocks Television Nov 05 2014
Skystar Bio-Pharma Featured on Wide World of Stocks Television Nov 05 2014
Skystar Bio-Pharmaceutical (SKBI) Upgraded From Hold to Buy Sep 09 2014
Skystar to Launch Probiotic Supplement for Dairy Cows by End of Fiscal 2014 Aug 26 2014
Skystar Bio-Pharmaceutical Reports Second Quarter Fiscal Year 2014 Financial Results Aug 14 2014
Skystar Bio-Pharmaceutical to File Financial Results for Second Quarter of Fiscal 2014 on Thursday,... Aug 14 2014
SKYSTAR BIO-PHARMACEUTICAL CO Files SEC form 10-Q, Quarterly Report Aug 14 2014

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK